Cognis sets up Indian subsidiary
This article was originally published in Scrip
Cognis has set up a wholly-owned subsidiary, Cognis Specialty Chemicals, in Mumbai. Cognis, which first opened a liaison office in India in February last year, expects the new affiliate to continue to grow its business in the country. Last year Cognis' sales in India grew by about 30%. The company supplies innovative ingredients for products such as pharmaceuticals, personal and home care, food ingredients and dietary supplements and has been increasingly allocating resources to its operations in the Asia-Pacific region. This is now its third-biggest market after Europe and North America. Cognis is owned by private equity funds advised by Permira, GS Capital Partners, and SV Life Sciences.
You may also be interested in...
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.